Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Aurora B kinase: a potential drug target for cancer therapy
Azaj Ahmed, Anas Shamsi, Taj Mohammad, et al.
Journal of Cancer Research and Clinical Oncology (2021) Vol. 147, Iss. 8, pp. 2187-2198
Closed Access | Times Cited: 22

Showing 22 citing articles:

Structure-guided identification of potential MTH1 inhibitors from natural compounds: toward therapeutic targeting of oxidative DNA damage in cancer
Aaliya Taiyab, Taj Mohammad, Md Nayab Sulaimani, et al.
Chemical Papers (2025)
Closed Access
Implications of tempol in pyruvate dehydrogenase kinase 3 targeted anticancer therapeutics: Computational, spectroscopic, and calorimetric studies
Saleha Anwar, Debarati DasGupta, Alaa Shafie, et al.
Journal of Molecular Liquids (2022) Vol. 350, pp. 118581-118581
Closed Access | Times Cited: 20
AURKB targets DHX9 to promote hepatocellular carcinoma progression via PI3K/AKT/mTOR pathway
Guoqing Zhu, Laihui Luo, Yongzhu He, et al.
Molecular Carcinogenesis (2024) Vol. 63, Iss. 9, pp. 1814-1826
Open Access | Times Cited: 2
An analysis of AURKB's prognostic and immunological roles across various cancers
J. Li, Cui Cheng, Jiajun Zhang
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 12
Open Access | Times Cited: 2
Role of aurora kinase B in regulating resistance to paclitaxel in breast cancer cells
Min Liu, Yinan Li, Cui Zhang, et al.
Human Cell (2022) Vol. 35, Iss. 2, pp. 678-693
Open Access | Times Cited: 12
CK1 Is a Druggable Regulator of Microtubule Dynamics and Microtubule-Associated Processes
Aileen Roth, Adrian Gihring, Joachim Bischof, et al.
Cancers (2022) Vol. 14, Iss. 5, pp. 1345-1345
Open Access | Times Cited: 12
Comprehensive Computational Analysis of Honokiol Targets for Cell Cycle Inhibition and Immunotherapy in Metastatic Breast Cancer Stem Cells
Skolastika Skolastika, Naufa Hanif, Muthi Ikawati, et al.
Evidence-based Complementary and Alternative Medicine (2022) Vol. 2022, pp. 1-18
Open Access | Times Cited: 9
Role of AURKB Inhibition in Reducing Proliferation and Enhancing Effects of Radiotherapy in Triple-Negative Breast Cancer
Sierra Pellizzari, Harjot Athwal, Anne C. Bonvissuto, et al.
Breast Cancer Targets and Therapy (2024) Vol. Volume 16, pp. 341-346
Open Access | Times Cited: 1
The overview of Mitogen-activated extracellular signal-regulated kinase (MEK)-based dual inhibitor in the treatment of cancers
Hao Wang, Lingling Chi, Fuqiang Yu, et al.
Bioorganic & Medicinal Chemistry (2022) Vol. 70, pp. 116922-116922
Closed Access | Times Cited: 7
The Role of Aurora B Kinase in Normal and Cancer Cells
E. V. Titova, Galina Shagieva, Vera B. Dugina, et al.
Biochemistry (Moscow) (2023) Vol. 88, Iss. 12-13, pp. 2054-2062
Closed Access | Times Cited: 3
The Aurora kinase B relocation blocker LXY18 triggers mitotic catastrophe selectively in malignant cells
Julia Kalashova, Chenglu Yang, Hongmei Li, et al.
PLoS ONE (2023) Vol. 18, Iss. 10, pp. e0293283-e0293283
Open Access | Times Cited: 2
Aurora kinase: An emerging potential target in therapeutics
Nidhi Varshney, Annu Rani, Dharmendra Kashyap, et al.
Elsevier eBooks (2022), pp. 261-322
Closed Access | Times Cited: 4
Exploring the anticancer potential of fluoro flavone analogues: insights from molecular docking and dynamics studies with Aurora Kinase B
Ipsa A. Singh, Kiran Bharat Lokhande, K. Venkateswara Swamy
In Silico Pharmacology (2024) Vol. 12, Iss. 1
Closed Access
MUC1-C Dependence for the Progression of Pancreatic Neuroendocrine Tumors Identifies a Druggable Target for the Treatment of This Rare Cancer
Hiroki Ozawa, Naoki Haratake, Ayako Nakashoji, et al.
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1509-1509
Open Access
Recent advancements in mechanistic Research, therapeutic Potential, and Structure-Activity relationships of Aurora kinase inhibitors in cancer therapies
Ghanshyam Teli, Lalmohan Maji, Rohit Pal, et al.
Bioorganic Chemistry (2024) Vol. 154, pp. 107976-107976
Closed Access
AURKB and circAURKB_288aa enhance Esophageal cancer drug resistance through inducing abnormal centrosome separation
Hongzhen Lv, Jing Zhou, Limin Qiu, et al.
Biochemical Pharmacology (2024) Vol. 232, pp. 116691-116691
Closed Access
The role of Aurora B kinase in normal and cancer cells
E. V. Titova, Galina Shagieva, Vera B. Dugina, et al.
Биохимия (2023) Vol. 88, Iss. 12, pp. 2435-2445
Closed Access | Times Cited: 1
Integrative Analysis for Elucidating Transcriptomics Landscapes of Systemic Lupus Erythematosus
Haihong Zhang, Yanli Wang, Jinghui Feng, et al.
Frontiers in Genetics (2021) Vol. 12
Open Access | Times Cited: 2
In-silico identification of novel inhibitors for human Aurora kinase B form the ZINC database using molecular docking-based virtual screening
Ashraf Ahmed Ali Abdusalam
Research Results in Pharmacology (2022) Vol. 8, Iss. 4, pp. 89-99
Open Access | Times Cited: 1
Influence of serum vitamin D level in the response of actinic keratosis to ingenol mebutate
Ricardo M. Alonso de Celada, Tamara Gracia‐Cazaña, Laura Nájera, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 12
Open Access
Six potential biomarkers for bladder cancer: key proteins in cell-cycle division and apoptosis pathways
Güldal İnal Gültekin, Özlem Timirci Kahraman, Murat İşbilen, et al.
Journal of the Egyptian National Cancer Institute (2022) Vol. 34, Iss. 1
Open Access
Efeitos moleculares e funcionais da inibição de MELK em linhagens de câncer de próstata
Caio César Damasceno Monção
(2022)
Open Access
Page 1

Scroll to top